FDA Drug recall D-0283-2024
Rifampin Capsules USP 150mg, 30-count bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc
- FDA Drug
- Class II
- terminated
- Published 2024-02-07
On 2024-02-07 the FDA classified a Class II recall of Rifampin Capsules USP 150mg, 30-count bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc by Lupin Pharmaceuticals, citing subpotent Drug and Failed Impurities/Degradation Specifications.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0283-2024 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2024-01-05 |
| Published | 2024-02-07 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Lupin Pharmaceuticals |
| Distribution | n/a |
Product
Rifampin Capsules USP 150mg, 30-count bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States, Manufactured Lupin Limited, Aurangabad 431 210 INDIA, NDC 68180-658-06
Reason
Subpotent Drug and Failed Impurities/Degradation Specifications
Identifiers
| ndc | 68180-658-06 |
|---|---|
| ndc | 68180-658-01 |
| ndc | 68180-659-06 |
| ndc | 68180-659-07 |
| ndc | 68180-659-01 |
| code_info | A200816 exp 1/2024 A201248 exp 3/2024 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0283-2024%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.